Articles tagged "Immunosuppression"

2020 American Transplant Congress
Immune Response Following Cardiac Progenitor Cells Transplantation in Rat Myocardial Infarction Model
M. Gunasekaran, R. Mishra, S. Sharma, P. Saha, L. Wang, M. Yasir Arfat, X. Fu, S. Kaushal
Surgery, University of Maryland, Baltimore, MD
*Purpose: Cardiac progenitor cells (CPCs, c-kit+) are well-characterized stem cell type shown to potentiate cardiac regeneration in myocardial infarct (MI) model. However, auto and allo…
2020 American Transplant Congress
Development of DSA Class II is Associated with Immunosuppressive Monotherapy and Increased Risk for Graft Fibrosis, Chronic Rejection and Graft Loss
M. Sterneck¹, B. Sultani¹, A. Ozga², S. Weidemann³, J. Hermann⁴, E. Grabhorn⁵, U. Herden⁶, L. Fischer⁶
¹University Medical Center Hamburg Eppendorf, Hamburg, Germany, ²Insitute of Medical Biometry, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ³Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁴Pediatric Radiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁵Pediatric Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁶Transplant Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
*Purpose: Recent studies have suggested a negative impact of class 2 DSA on short term outcome of OLT recipients. The aim of this study was…
2020 American Transplant Congress
Targeted Urine Metabolomics for Monitoring Renal Allograft Injury and Immunosuppression
T. Sigdel, A. Schroeder, J. Y. Yang, R. Sarwal, J. Liberto, M. Sarwal
University of California San Francisco, San Francisco, CA
*Purpose: The purpose of this study was to apply high-throughput metabolomics and machine learning to identify surrogate urine metabolite biomarkers for acute rejection vs. BK…
2020 American Transplant Congress
Analysis of Rejection, Rejection Therapy and Renal Function in the BEST Trial
H. Kuzaro¹, A. R. Shields², A. Wiseman³, S. Tremblay¹, A. Christianson¹, D. Kaufman⁴, J. Leone⁵, A. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²The Christ Hospital, Cincinnati, OH, ³U Colorado, Denver, CO, ⁴U Wisconsin, Madison, WI, ⁵Tampa General, Tampa, FL, ⁶U Minnesota, Minneapolis, MN, ⁷UIC, Chicago, IL
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal) compared two belatacept (BELA)-based early corticosteroid withdrawal (ESW) regimens and alemtuzumab (ALEM) or rabbit antithymocyte globulin (rATG)…
2020 American Transplant Congress
Large Academic Center Experience with Treatment of Suspected/Confirmed Kidney Transplant Active Antibody Mediated Rejection
J. T. Reece¹, B. A. Steiner², V. Bhoj¹, N. Aqui¹, R. D. Bloom³, J. Trofe-Clark⁴
¹Transfusion Medicine Div, Univ of Pennsylvania, Philadelphia, PA, ²Pharmacy, Hosp of Univ of Pennsylvania, Philadelphia, PA, ³Renal Div, Univ of Pennsylvania, Philadelphia, PA, ⁴Pharmacy, Hospital of University of Pennsylvania, Philadelphia, PA
*Purpose: Therapeutic plasma exchange (TPE) and intravenous immunoglobulin (IVIG) are common active antibody mediated rejection (ABMR) treatments in kidney transplant recipients (KTRs), but with unclear…
2020 American Transplant Congress
Graft versus Host Disease in a Liver Transplant Patient
D. Francisco, L. Woc-Colburn, P. Nicholls, M. Hemmersbach-Miller
Department of Infectious Diseases, Baylor College of Medicine, Houston, TX
*Purpose: Graft versus host disease (GVHD) is a rare cause of morbidity and mortality in solid organ transplant (SOT) recipients; the estimated prevalence is 1-2%…
2020 American Transplant Congress
A Single Nucleotide Polymorphism of Tweak Predicts Arterio- and Arteriolohyalinosis in Kidney Transplants and is Associated with Allograft Survival
A. Karolin¹, D. Thottan¹, J. Zinsli¹, S. Rudloff¹, U. Huynh-Do¹, V. Banz², T. Berney³, M. Pascual⁴, T. Müller⁵, P. d’Amico⁶, I. Binet⁷, D. Sidler¹
¹Nephrology and Hypertension, University Bern, Bern, Switzerland, ²University Bern, Bern, Switzerland, ³University Hospital Genevia, Genevia, Switzerland, ⁴University Hospital Lausanne, Lausanne, Switzerland, ⁵University Hospital Zurich, Zurich, Switzerland, ⁶Hospital St.Gallen, St.Gallen, Switzerland, ⁷University Hospital Basel, Basel, Switzerland
*Purpose: We have recently demonstrated that the TNF superfamily member is critical for the pathogenesis of Calcineurin Inhibitor Toxicity (CNT). CNT is a common side…
2020 American Transplant Congress
The Oncological Optimal Tacrolimus Target Level after Liver Transplant for Hepatocellular Carcinoma
K. Sasaki¹, J. McVey¹, D. Firl², Y. Inaba³, C. D. Kwon¹, K. Hashimoto¹, F. Aucejo¹
¹The Cleveland Clinic, Cleveland, OH, ²Duke University, Durham, NC, ³Chiba University, Chiba, Japan
*Purpose: The recurrence rate after liver transplant (LT) for hepatocellular carcinoma (HCC) is high as 15-20% nevertheless of complete removal of tumor and carcinogenic liver.…
2020 American Transplant Congress
Simultaneous Pancreas-Kidney Transplant: – The Effects of Early Steroid Withdrawal, Donor and Recipient Variables on Patient Survival
D. Kloda¹, M. McLeod², M. Romine¹, J. Ladowski², J. Locke¹, C. Young¹
¹Department of Surgery - Division of Transplantation, University of Alabama, Birmingham, AL, ²Department of Surgery, University of Alabama, Birmingham, AL
*Purpose: Simultaneous pancreas-kidney transplantation (SPK) improves survival in type I diabetic patients with end stage renal disease (ESRD). Corticosteroids have traditionally been an integral component…
2020 American Transplant Congress
Sparing the Nephron in Liver Transplant Recipients with Antithymocyte Bridging: A Four Year Experience
N. Wilson, H. Kuzaro, N. Parrish, S. A. Shah, N. Anwar, R. R. Alloway, S. Tremblay, T. E. Kaiser
U Cincinnati, Cincinnati, OH
*Purpose: Renal function decline after liver transplant (LT) remains a significant issue. Using antithymocyte globulin (rATG) to delay tacrolimus (TAC) initiation may impact renal deterioration;…